<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Kaspar Rufibach on Kaspar Rufibach</title>
    <link>https://numbersman77.netlify.com/</link>
    <description>Recent content in Kaspar Rufibach on Kaspar Rufibach</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <copyright>&amp;copy; 2019</copyright>
    <lastBuildDate>Mon, 01 Feb 2021 00:00:00 +0100</lastBuildDate>
    <atom:link href="/" rel="self" type="application/rss+xml" />
    
    <item>
      <title>How can the estimand framework support decentralized trials?</title>
      <link>https://numbersman77.netlify.com/talk/invited/2021_1_lungevity/</link>
      <pubDate>Mon, 01 Feb 2021 00:00:00 +0100</pubDate>
      
      <guid>https://numbersman77.netlify.com/talk/invited/2021_1_lungevity/</guid>
      <description>&lt;!-- Embed your slides or video here using [shortcodes](https://sourcethemes.com/academic/post/writing-markdown-latex/). Further details can easily be added using *Markdown* and $\rm \LaTeX$ math code. --&gt;
</description>
    </item>
    
    <item>
      <title>2021/02: Answering Old Questions with New Tools: Application of the ICH E9 Addendum in Oncology</title>
      <link>https://numbersman77.netlify.com/teaching/stats/202102_roche_estimands/</link>
      <pubDate>Sun, 31 Jan 2021 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/teaching/stats/202102_roche_estimands/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Title&lt;/strong&gt;: Answering Old Questions with New Tools: Application of the ICH E9 Addendum in Oncology&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Speakers&lt;/strong&gt;: Kaspar Rufibach and Godwin Yung, Roche&lt;/p&gt;

&lt;p&gt;This is a re-hash of the Deming conference course I gave with Evgeny Degtyarev, see &lt;a href=&#34;https://numbersman77.netlify.app/teaching/stats/202012_demings_estimands/&#34; target=&#34;_blank&#34;&gt;here&lt;/a&gt; for details.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Conditional Power and Friends: The Why and How of (Un)planned, Unblinded Sample Size Recalculations in Confirmatory Trials</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2021_07_reestimation/</link>
      <pubDate>Thu, 07 Jan 2021 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2021_07_reestimation/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) - comparison of adverse event risks in randomized controlled trials</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2021_06_savvy_2sample/</link>
      <pubDate>Wed, 06 Jan 2021 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2021_06_savvy_2sample/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) - estimation of adverse event risks</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2021_05_savvy_1sample/</link>
      <pubDate>Tue, 05 Jan 2021 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2021_05_savvy_1sample/</guid>
      <description></description>
    </item>
    
    <item>
      <title>A review of Bayesian perspectives on sample size derivation for confirmatory trials</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2021_04_bayes_samplesize/</link>
      <pubDate>Mon, 04 Jan 2021 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2021_04_bayes_samplesize/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Estimands for Overall Survival in Clinical Trials with Treatment Switching</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2021_03_estimand_switching/</link>
      <pubDate>Sun, 03 Jan 2021 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2021_03_estimand_switching/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Principal Stratum Strategy: Potential Role in Drug Development</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2021_02_principal_stratification/</link>
      <pubDate>Sat, 02 Jan 2021 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2021_02_principal_stratification/</guid>
      <description></description>
    </item>
    
    <item>
      <title>2021/02: Introduction to statistics.</title>
      <link>https://numbersman77.netlify.com/teaching/nonstats/2021_1_pdma_basel/</link>
      <pubDate>Fri, 01 Jan 2021 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/teaching/nonstats/2021_1_pdma_basel/</guid>
      <description>&lt;p&gt;Two 2-hour courses for all Medical Science Liaison colleagues within Medical Affairs (virtual event).&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Estimands in Hematology Trials</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2021_01_heme_estimand/</link>
      <pubDate>Fri, 01 Jan 2021 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2021_01_heme_estimand/</guid>
      <description></description>
    </item>
    
    <item>
      <title>2020/12: Answering Old Questions with New Tools: Application of the ICH E9 Addendum in Oncology</title>
      <link>https://numbersman77.netlify.com/teaching/stats/202012_demings_estimands/</link>
      <pubDate>Tue, 01 Dec 2020 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/teaching/stats/202012_demings_estimands/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Title&lt;/strong&gt;: Answering Old Questions with New Tools: Application of the ICH E9 Addendum in Oncology&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Speakers&lt;/strong&gt;: Kaspar Rufibach, Roche and Evgeny Degtyarev, Novartis&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Moderator&lt;/strong&gt;: Kalyan Ghosh&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;:&lt;/p&gt;

&lt;p&gt;This shortcourse will discuss the application of the ICH E9(R1) estimand addendum to oncology clinical trials. Using examples we will illustrate how the estimand framework supports transparent formulation of clinical trial objective(s) for challenging drug development questions such as&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;treatment switching,&lt;/li&gt;
&lt;li&gt;complexity of treatment options and existence of potential curative procedures or treatment sequence across different phases in hematological trials,&lt;/li&gt;
&lt;li&gt;the use of a principal stratum estimand to assess the impact of post-randomization events such as development of antidrug antibodies on efficacy or safety of a new drug.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Often, such type of questions are answered using simplified analyses that are only valid under strong assumptions. To make these assumptions transparent we will discuss estimands, estimation methods, impact on data collection, and experiences with Health Authorities for these scenarios. Finally, we will share our experience in implementing the addendum in large pharmaceutical companies, within biostatistics and for other partner functions.&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;&lt;a href=&#34;https://demingconference.org/topic/session-j/&#34; target=&#34;_blank&#34;&gt;Announcement&lt;/a&gt; of the course on the conference webpage (incl. speaker bios).&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://oncoestimand.github.io/oncowg_webpage/talks/Deming2020_ED_KR_estimands_oncology.pdf&#34; target=&#34;_blank&#34;&gt;Slidedeck&lt;/a&gt;.&lt;/li&gt;
&lt;li&gt;Learn more about the oncology estimand WG on its &lt;a href=&#34;http://www.oncoestimand.org&#34; target=&#34;_blank&#34;&gt;webpage&lt;/a&gt;.&lt;/li&gt;
&lt;/ul&gt;
</description>
    </item>
    
    <item>
      <title>A deep dive into principal stratification and causal inference</title>
      <link>https://numbersman77.netlify.com/talk/invited/2020_8_effstat_podcast/</link>
      <pubDate>Tue, 17 Nov 2020 00:00:00 +0100</pubDate>
      
      <guid>https://numbersman77.netlify.com/talk/invited/2020_8_effstat_podcast/</guid>
      <description>&lt;p&gt;Principal stratification used to play a role only in observational research but at least since the addendum of the ICH E9 guideline, this approach to causal inference became a hot topic.&lt;/p&gt;

&lt;p&gt;We cover the following questions:&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;What is Principal Stratification?&lt;/li&gt;
&lt;li&gt;How would you describe principal stratification to a non-statistician?&lt;/li&gt;
&lt;li&gt;Where do you see the benefits of this estimand compared to the other typical strategies?&lt;/li&gt;
&lt;li&gt;Which critique points do are usually raised against this approach?&lt;/li&gt;
&lt;li&gt;How do you implement/calculate corresponding estimates for this estimand?&lt;/li&gt;
&lt;li&gt;What references would you recommend for further reading?&lt;/li&gt;
&lt;/ul&gt;
</description>
    </item>
    
    <item>
      <title>Estimands update: Summary of world-wide authority interaction</title>
      <link>https://numbersman77.netlify.com/talk/invited/2020_9_apf_estimands/</link>
      <pubDate>Tue, 17 Nov 2020 00:00:00 +0100</pubDate>
      
      <guid>https://numbersman77.netlify.com/talk/invited/2020_9_apf_estimands/</guid>
      <description>&lt;p&gt;Talk given together with Hannes Buchner from Staburo.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>github repository and markdown file for SAVVY project: Survival analysis for AdVerse events with VarYing follow-up times</title>
      <link>https://numbersman77.netlify.com/software/savvy/</link>
      <pubDate>Sun, 06 Sep 2020 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/software/savvy/</guid>
      <description>&lt;p&gt;The code in this github repository allows to compute the various estimators analyzed in the SAVVY project.&lt;/p&gt;

&lt;p&gt;&lt;a href=&#34;https://github.com/numbersman77/AEprobs&#34; target=&#34;_blank&#34;&gt;github repository&lt;/a&gt;&lt;br&gt;
&lt;a href=&#34;https://numbersman77.github.io/AEprobs/SAVVY_AEprobs.html&#34; target=&#34;_blank&#34;&gt;markdown&lt;/a&gt;&lt;br&gt;
&lt;a href=&#34;https://arxiv.org/abs/1912.00263&#34; target=&#34;_blank&#34;&gt;Paper: Statistical Analysis Plan of SAVVY project&lt;/a&gt;&lt;br&gt;
&lt;a href=&#34;https://arxiv.org/abs/2008.07883&#34; target=&#34;_blank&#34;&gt;Paper: Estimation of AE risks&lt;/a&gt;&lt;br&gt;
&lt;a href=&#34;https://arxiv.org/abs/2008.07881&#34; target=&#34;_blank&#34;&gt;Paper: Comparison of AE risk in a two-arm RCT&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>github repository and markdown file for different analysis methods for principal stratum estimands motivated by the principal ignorability assumption</title>
      <link>https://numbersman77.netlify.com/software/principalstratification/</link>
      <pubDate>Thu, 13 Aug 2020 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/software/principalstratification/</guid>
      <description>&lt;p&gt;The code in this github repository allows to reproduce all computations in the paper &amp;ldquo;Principal Stratum Strategy: Potential Role in Drug Development&amp;rdquo;.&lt;/p&gt;

&lt;p&gt;&lt;a href=&#34;https://github.com/oncoestimand/princ_strat_drug_dev&#34; target=&#34;_blank&#34;&gt;github repository&lt;/a&gt;&lt;br&gt;
&lt;a href=&#34;https://oncoestimand.github.io/princ_strat_drug_dev/princ_strat_example.html&#34; target=&#34;_blank&#34;&gt;markdown&lt;/a&gt;&lt;br&gt;
&lt;a href=&#34;https://arxiv.org/abs/2008.05406&#34; target=&#34;_blank&#34;&gt;paper&lt;/a&gt;&lt;br&gt;&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
